Most Oncologists Feel New Genetic Test for Tamoxifen Sensitivity Not Ready for the Clinic

(PhysOrg.com) -- Despite commercial availability and direct to consumer marketing of a new genetic test designed to reveal a breast cancer patient`s sensitivity to tamoxifen, most physicians in the U.S. are not currently using it to guide treatment, according to research from Duke University Medical Center presented today at the CTRC-AACR San Antonio Breast Cancer Symposium.

Read the whole article on Physorg

More from Physorg